Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 18, 2022 07:00 ET | Source: Passage Bio

Passage Bio Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at ASGCT 25th Annual Meeting

Longer-term follow-up showed continued developmental improvement for both patients in assessments by study investigators and caregiversInterim safety data at 13 and seven months from patients in...
May 16, 2022 07:00 ET | Source: Passage Bio

Passage Bio Reports First Quarter 2022 Financial Results and Provides Recent Business Highlights

Dosed first patient in Cohort 2 and completed dosing of Cohort 3 in Imagine-1 clinical trial for GM1 gangliosidosis; interim safety and biomarker data for both cohorts expected in 2H22Dosed first...
May 09, 2022 07:00 ET | Source: Passage Bio

Passage Bio to Report First Quarter 2022 Financial Results on May 16, 2022

PHILADELPHIA, May 09, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
May 03, 2022 14:13 ET | Source: Passage Bio

UPDATE - Passage Bio to Present Updated Imagine-1 Study Clinical and Biomarker Data at the American Society of Gene and Cell Therapy 25th Annual Meeting

PHILADELPHIA, May 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
May 02, 2022 16:01 ET | Source: Passage Bio

Passage Bio to Present Updated Imagine-1 Study Clinical and Biomarker Data at the American Society of Gene and Cell Therapy 25th Annual Meeting

PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
April 22, 2022 16:01 ET | Source: Passage Bio

Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, April 22, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
March 29, 2022 07:00 ET | Source: Passage Bio

Passage Bio Announces Publication of Preclinical Data that Support Ongoing Clinical Study of PBKR03 in Krabbe Disease

Preclinical studies conducted with University of Pennsylvania’s Gene Therapy Program demonstrate biologic effects of vector-optimized gene therapy PBKR03 for Krabbe diseasePBKR03 showed marked...
March 28, 2022 07:00 ET | Source: Passage Bio

Passage Bio to Participate in Upcoming Investor Conferences

PHILADELPHIA, March 28, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
March 15, 2022 07:00 ET | Source: Passage Bio

Passage Bio Provides Update on Strategic Priorities and Extends Cash Runway

Company to reduce workforce and prioritize research and development programs to reduce operating expensesContinued focus on execution of three ongoing clinical trials for GM1 gangliosidosis, Krabbe...
March 10, 2022 07:00 ET | Source: Passage Bio

Passage Bio Doses First Patient in Global Clinical Trial for Infantile Krabbe Disease, A Rare Fatal Pediatric Condition

PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...